Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection  by Seshadri, Ramanathan M. et al.
ORIGINAL ARTICLE
Survival analysis of patients with stage I and II hepatocellular
carcinoma after a liver transplantation or liver resection
Ramanathan M. Seshadri1, Siddesh Besur2, David J. Niemeyer1, Megan Templin3, Iain H. McKillop1, Ryan Z. Swan1,
John B. Martinie1, Mark W. Russo2 & David A. Iannitti1
1Hepato-Pancreato-Biliary Surgery, Department of Surgery, 2Division of Hepatology, Department of Internal Medicine, and 3Dickson Advanced Analytics
Group, Carolinas Medical Center, Charlotte, NC, USA
Abstract
Introduction: Liver transplantation (LT) is a treatment option in select patients with hepatocellular
carcinoma (HCC). The aim of the present study was to compare survival in Stage I or II HCC patients
undergoing either liver transplant (LT) or a liver resection (LR).
Method: The study is a retrospective analysis of the National Cancer Data Base (1998–2011). In total,
148 882 patients with liver cancer were identified, of which 5-year survival data (1998–2006) were
available for 64 227 patients. Patients were stratified by the American Joint Committee on Cancer (AJCC)
clinical stage I and II. Kaplan–Meier curves and log-rank tests were used for statistical analysis.
Results: 3340 HCC patients met analysis criteria. Among stage I HCC, 860 had LT and 871 had LR.
Among stage II HCC, 833 had LT and 776 LR. In stage I patients the median survival for LT and LR were
127.9 and 56.7 months, respectively, (P < 0.0001) and in stage II patients the median survival was 110.8
and 42.8 months (P < 0.0001). Unlike LT patients, LR patients with Stage I HCC had a longer median
survival compared with Stage II patients (P = 0.0002).
Conclusion: Liver transplantation offers a survival advantage compared with a liver resection among
patients with Stage I and II HCC. LT is the best surgical treatment for early stage (I/II) HCC in patients with
advanced fibrosis or cirrhosis, whereas LR provides equivalent outcomes to LT in patients without
advanced fibrosis and should be considered as the first surgical option.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary
hepatic malignancy with over 30 000 cases diagnosed and 20 000
deaths per year in the United States.1 The incidence is on the rise
with more patients being diagnosed with non-alcoholic fatty liver
disease.2,3 Screening patients with underlying liver disease for
HCC is variable; hence, patients often present with advanced
disease at the time of diagnosis, which may preclude surgical
treatment.4,5 The majority of patients develop HCC in the back-
ground setting of cirrhosis, especially in regions (western coun-
tries) where alcohol consumption and chronic hepatitis C serve as
the primary aetiology of liver disease.2 This is different from the
population developing HCC in eastern countries where Hepatitis
B is the most common cause.
The prognosis of patients with HCC depends not only on the
stage of the disease, but also on liver function at the time of
diagnosis. Long-term disease-free survival can be achieved by sur-
gically removing the tumour. The treatment for early stage disease
in patients with preserved liver function is a liver resection
(LR).6–14 With the advent of liver transplantation (LT) and effec-
tive immunosuppression, unresectable candidates can also be
effectively treated.15–17 The treatment of choice for patients with
advanced cirrhosis and HCC within the Milan criteria is LT;
however, owing to the national shortage of organs, LT remains
limited and is only an available option for a select group of
patients.18
This study was presented, in part, as a long-oral presentation at the Annual
Meeting of the AHPBA, 19-23 February 2014, Miami, Florida.
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Several previous studies have compared LR with LT for HCC to
determine the relative benefits and risks of each procedure.19–24
The largest study published to date was a meta-analysis by Zheng
et al., that analysed 62 studies comparing LT and LR for HCC.
Overall, these data reported increased survival and lower recur-
rence rates for LT compared with LR.25 Similarly, several single-
centre retrospective studies conclude LT should be considered as
the primary treatment of HCC for those patients that fall within
the Milan criteria26,27 Conversely, studies by Facciuto et al. report
survival rates for HCC patients are similar after LR and LT.28
Multiple patient- and tumour-related factors dictate the
optimal treatment option for patients with HCC, including
patient general health, extent of liver fibrosis/cirrhosis and
tumour location/number/size. As a result, few studies address
comparative outcomes for early stage HCC patients undergoing
LT compared with LR. Early stage HCC patients [stratified by The
American Joint Committee on Cancer (AJCC) Clinical Stage I and
II – Table 1]29,30 are more likely to meet the Milan criteria and are
therefore more likely to be eligible for LT. In order to compare
long-term outcomes for LT compared with LR in Stage I and Stage
II HCC patients, we sought permission to access medical infor-
mation contained in the National Cancer Data Base (NCDB) via
the American College of Surgeons.
Instituted in 1989 the NCDB is a nationwide oncology out-
comes database from more than 1500 commission-accredited
cancer programmes in the United States and Puerto Rico.31 It is a
joint programme of the Commission on Cancer (CoC), the
American College of Surgeons and the American Cancer Society.
Approximately 70% of all newly diagnosed cancers are captured at
the centre and submitted to the NCDB. In all, the NCDB now
contains ≈29 million records from hospital cancer registries across
the United States and Puerto Rico. The key components of the
database include patient demographics, cancer diagnostics, clini-
cal and pathological staging, treatment details (surgery, radiation,
chemotherapy and palliative) and survival. In addition, socio-
economic information and insurance information is also
captured.
Patients and methods
Data acquisition and patient selection
Access to the NCDB database was obtained after submitting an
online proposal requesting participant user files (http://
ncdbpuf.facs.org/) Patients with primary HCC were identified
using codes 8170–8175 according to the International Classifica-
tion of Diseases for Oncology.36 This approach provided data on
149 020 patients diagnosed with liver cancer between 1998–2011.
We restricted the cohort to 1998–2006 to allow us to obtain accu-
rate 5-year survival data from time of diagnosis. (Fig. 1). A total of
3340 patients with clinical stage I and II HCC were included in the
final case cohort. The pre-operative (clinical) staging was used as
the decision to resect versus transplant with early stage HCC was
made based (largely) on the clinical staging of the disease. The
AJCC clinical staging 5th edition was used from 1998–2002 and
the 6th edition was used from 2003–2006. We used the informa-
tion as recorded in the database to perform our study keeping the
key changes between the 5th and 6th editions in mind (Table 1).
All these patients had information for the subgroup analyses in
the database except for tumour size (3145/3400).
Statistical analysis
Statistical analysis was performed using SAS Enterprise Guide®, V.
5.1. (SAS Institute, Inc., Cary, NC, USA). Descriptive statistics,
including counts, percentages, means and standard deviations,
were calculated for patient-specific demographics. Survival was
calculated in months from date of diagnosis to date of death, or
date of last contact. Overall survival was derived using Kaplan–
Meier estimates and the log-rank test was used to analyse statisti-
cal significance of Kaplan–Meier estimates. Cox’s proportional
hazard models were used for univariate and multivariate analyses
of time-to-event data and multivariate Cox’s proportional hazard
models adjusted for procedure, stage, tumour size, age and gender.
A two-tailed P < 0.05 was considered significant.
Results
Patient demographics
In total, 77 460 patients were diagnosed and recorded to the
NCDB with liver cancer (1998–2006), of which 64 264 (83.0%)
had HCC as their primary diagnosis (Fig. 1). Within this group of
HCC patients 13 790 (21.5%) were diagnosed as Stage I or II, of
who 3340 (24.2%) underwent either LR [n = 1647 (49.3%); n =
871 Stage I (50.3%), n = 776 Stage II (49.7%)] or LT [n = 1693
(50.7%); n = 860 Stage I; n = 833 Stage II (49.3)] (Fig. 1). Within
the Stage I/II HCC population undergoing LT or LR males out-
numbered females by approximately 2:1 [2338 (70.0%)/1002
Table 1 AJCC clinical staging (5th and 6th edition) for Stage I & II HCC
AJCC clinical staging 5th edition (1998–2002) AJCC clinical staging 6th edition (2003–2006)
Stage I – T1 N0 M0 Stage I – T1 N0 M0
Stage II – T2 N0 M0 Stage II – T2 N0 M0
T1 – Solitary tumour 2 cm or less in greatest dimension without vascular
invasion
T1 – Solitary tumour without vascular invasion
T2 – Solitary tumour 2 cm or less in greatest dimension with vascular
invasion or multiple tumors limited to 1 lobe (none < 2 cm without vascular
invasion), or a solitary tumor > 2 cm without vascular invasion
T2 – Solitary tumour with vascular invasion or multiple
tumours none > 5 cm
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(30.0%)] with a comparable ratio of males and females undergo-
ing LR compared with LT (1123 versus 1215, LR versus LT; males;
524 versus 478, LR versus LT; females). The mean age of LT
patients was significantly lower than LR patients [62.8 ± 12.9 (LR)
versus 55.7 ± 7.8 (LT)]. Demographic details of the case cohort are
provided in Table 2.
Survival data
For patients diagnosed with Stage I or Stage II HCC the median
survival for those undergoing LT was significantly better than LR
[127.9 (107.9–180) and 56.7 (51.8–65.1) months, respectively, for
Stage I, P < 0.0001, and 110.8 (103.7–150.5) and 42.8 (38.3–48.9)
months, respectively, for Stage II, P < 0.0001, Fig. 2]. Unlike LT
Figure 1 Flowchart representing selection of patient cohort for the study
Table 2 Demographics table
Resection Stage 1 Resection Stage 2 Transplant Stage 1 Transplant Stage 2
n 871 776 860 833
Mean age (years) 63.0 62.7 55.6 55.8
Gender Male 597 526 651 664
Female 274 250 209 169
Tumour size < = 2 cm 133 57 349 216
>2 cm 676 679 464 571
Unknown 62 40 47 46
Fibrosis None – moderate 85 37 38 22
Severe – cirrhosis 48 22 130 139
Missing 738 717 692 672
AFP Elevated 227 124 258 267
Normal 172 56 115 93
Borderline 1 1 1 2
Missing 471 595 486 471
AFP, alpha fetoprotein.
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patients, LR patients with Stage I HCC had a longer median
survival compared with Stage II patients (P = 0.0002).
To further analyse independent risk factors we employed a Cox
model to include age, gender, size of tumour and clinical stage.
Females had a 18% decreased risk of mortality compared with
males when undergoing a LT or LR in the adjusted model
(Table 3). This remained true when the Cox model was applied to
resection alone (P = 0.0006) but there was no difference in mor-
tality between males and females when the Cox Model was applied
to the transplant group alone (P = 0.5775).
Subgroup analysis
Chemotherapy
This variable is documented only as ‘single’ agent or ‘multiagent’
chemotherapy in the database. All patients who had undergone
transarterial chemoembolization (TACE) were also grouped in
this category. To date, patients who had single or multi drug
chemotherapy for Stage I HCC had similar survival outcomes if
they underwent LT or LR (median survival for LR = >150, LT =
155.04, P = 0.671, Fig. 3a). However, patients who underwent LR
for Stage I HCC with chemotherapy had a better survival than
Figure 2 Kaplan–Meier survival curves – overall survival (transplant versus resection). SI LT, Stage 1 liver transplant; SII LT, Stage 2 liver
transplant; S1 LR, Stage 1 liver resection; and SII LR, Stage 2 liver resection
Table 3 Cox model (transplant and resection)
Variables n Unadjusted Adjusted








LT / LR LT (ref) 1693
LR 1647 <0.0001 2.20 1.99 2.43 <.0001 1.792 1.6 2.006
Clinical Stage 1 (ref) 1731
2 1609 0.0008 1.18 1.07 1.30 0.0008 1.181 1.071 1.302
Tumor size <2 cm (ref) 755
>2 cm 2390 <0.0001 1.80 1.58 2.05 0.0002 1.294 1.127 1.485
Unknown 195 <0.0001 1.75 1.40 2.18 0.0273 1.29 1.029 1.617
Age 3340 <0.0001 1.036 1.032 1.041 <0.0001 1.025 1.02 1.029
Gender Male (ref) 2438
Female 902 0.6493 0.98 0.88 1.09 0.0005 0.823 0.738 0.918
LT/LR, Liver transplant/liver resection; ref, reference.
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those without chemotherapy (P < 0.0004, Fig. 3b). There was no
significant difference in survival for either Stage I or II HCC
patients who received chemotherapy in the LT group.
Tumour size
Data regarding tumour size (<2 versus >2 cm) were available for
3145 patients (1545 LR and 1600 LT patients). In cases with multi-
ple tumours, tumour size was defined as the tumour with the
largest diameter. We included tumour size as well as staging in
the model to see if tumour size alone was associated with survival.
The clinical staging includes tumour size plus vascular invasion
and multiplicity. We chose to dichotomize tumour size by less
than or greater than 2 cm because 2 cm is the minimum size that
qualifies for transplant. The primary tumour alone was taken into
consideration in determining size as the largest dimension of the
primary tumour was what was recorded in the data base. In this
study we deliberately opted to use both clinical stage and tumour
size in the Cox model as we had an interest in establishing whether
tumour size alone was a significant factor in outcome when com-
paring patients receiving a transplant compared with a resection.
Irrespective of tumour size, patients undergoing LT for Stage I or
II HCC had an improved survival compared with those undergoing
LR. However, patients with smaller tumours (<2 cm) had signifi-
cantly improved outcomes compared with tumours >2 cm, inde-
pendent of whether the patient underwent LT or LR (Table 4).
Fibrosis (based on the Ishak Score)
From 2004 on, the NCDB database started including data for
degree of fibrosis (none to moderate) (Ishak score 0–4; AJCC F0)
and severe to cirrhosis (Ishak score 5–6; AJCC F2). For our analysis
this provides fibrosis data for 192 (out of 900) LR patients and 329
(out of 1071) LT patients between 2004–2006 (i.e. data for which















<2 cm 88.84 155.04 <0.0001 59.5 >150 0.0007
>2 cm 54.9 104.67 <0.0001 42.38 103.72 <0.0001
P-value 0.0099 0.0007 0.0281 0.0305
Fibrosis
None – moderate (n = 182) 84.3 >150 0.2055 54.9 103.72 0.0945
Severe – cirrhosis (n = 339) 31.6 94.7 <0.0001 23.2 >150 <0.0001
AFP
Elevated (>500 ng/ml) (n = 876) 56.7 >150 <0.0001 40.2 >150 <0.0001
Normal (n = 436) 60.1 99.9 <0.0001 59.4 >150 0.0073
Figure 3 (a) Kaplan–Meier survival curves – chemotherapy for stage I hepatocellular carcinoma (HCC) (transplant versus resection); (b) effect
of chemotherapy for stage I HCC (resection)
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5-year survival is also available). As might be expected, more liver
resections were performed in patients with Ishak scores between
0–4 (122 LR versus 60 LT), whereas more transplants were per-
formed in patients with Ishak scores of 5–6 (269 LT versus 70 LR).
There was no significant difference in survival between patients
with Ishak scores between 0–4 (none to moderate fibrosis) under-
going LT compared with LR based on disease stage (P = 0.2055 for
stage I, P = 0.0945 for stage II, Table 2; Fig. 4). Conversely, a
significant difference in survival was identified between patients
with Stage I and II HCC undergoing LT compared with LR when
the Ishak scores were between 5 and 6 (i.e. severe fibrosis or
cirrhosis) (P < 0.0001 for stage I, P < 0.0001 for stage II; Table 4;
Fig. 4).
Alpha fetoprotein (AFP)
Alpha fetoprotein (AFP) data were available for 1312 patients with
Stage I or II HCC, of whom 579 underwent a resection and 733
received a transplant. Patients who underwent LT for Stage I or II
HCC had a better overall survival than patients who had LR
independent of AFP values. Normal AFP (P < 0.0001; Stage I
HCC, and P = 0.0073; stage II HCC) and elevated AFP (>500 ng/
ml) (P < 0.0001; Stage I HCC, and P < 0.01 for Stage II HCC)
(Table 4).
Discussion
Hepatocellular carcinoma is one of the leading causes of cancer-
related mortality in the world.1 The aim of this study was to
analyse outcomes of patients treated for early stage HCC (Stage
I/II) by LT or LR using data stored in the NCDB. Overall, the
median survival for LT recipients was significantly better com-
pared with LR patients for both stage I and II HCC (127.9 (107.9–
180) compared with 56.7 (51.8–65.1) months (Stage I), 110.8
(103.7–150.5) compared with 42.8 (38.3–48.9) months (Stage
II)). This is consistent with the meta-analysis performed by Zheng
et al. that reported LT recipients had significantly better overall
survival, disease-free survival and lower recurrence rates than LR
patients for HCC.25
The majority of studies that compare LT with LR for HCC are
single-centre studies. For example, Baccarani et al. analysed
patients with HCC, on an intention-to-treat basis, and confirmed
transplantation was superior to LR in terms of overall survival and
disease-free survival.9 Similarly, Lee et al. reported patients with
HCC and Childs A or B cirrhosis showed recurrence-free survival
to be significantly greater after LT compared with LR over a
10-year period.26 While our study further confirms these data, this
study is unique in that it uses data acquired from over 1500
Commission on Cancer accredited centres. This approach prob-
ably accounts for variability in outcomes between centres to
provide a more accurate representation of long-term outcomes on
a national scale. We were also able to look at extent of fibrosis,
tumour size, AFP levels and chemotherapy to determine each
variable’s effect as an independent risk factor for survival.
In a subset analysis of patients from 2004–2006 in which the
fibrosis score was recorded, these data demonstrate that patients
Figure 4 Kaplan–Meier survival curves – advanced fibrosis (transplant versus resection) SI LT, Stage 1 liver transplant; SII LT, Stage 2 liver
transplant; S1 LR, Stage 1 liver resection; SII LR, Stage 2 liver resection
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with advanced fibrosis (n = 339) (Ishak Score 5–6) and HCC
derived a survival benefit from LT compared with LR (94.7 versus
31.6 months, Stage I HCC, and >150 versus 23.2 months, Stage II
HCC)(Table 2), whereas patients with Ishak Scores 0–4 (n = 182)
and HCC did equally well with LR as they did with transplant
(P= 0.2055 for Stage I HCC;P= 0.0945 for Stage II HCC) (Table 2).
These data suggest that this patient population would benefit
equally from a LR as first choice of therapy. The fibrosis score was
included in the NCDB data set starting in 2004; therefore, further
analysis of the effect of the fibrosis score on survival will need to be
assessed in the later time period from 2006–2011. Interestingly
although, our analysis revealed LT recipients had an overall better
survival than LR patients independent of either tumor size or AFP
levels (Table 2). While limited data were available regarding the use
of chemotherapy as part of the treatment in the study groups, our
analyses did demonstrate that patients with Stage I HCC who
underwent a LR in conjunction with chemotherapy had a longer
survival than those undergoing LR alone. However, it should noted
that the information contained within this database meant it was
not possible to ascertain the time of chemotherapy relative to other
parameters for these patient groups and the fact that all patients in
the study group who received TACE (most likely all of them) were
grouped into the chemotherapy section.
Over the past decade the number of patients transplanted for
HCC has increased significantly and studies indicate there has
been a relative shift away from LR towards LT for HCC patients.32
Current expert opinion indicates LT is the best treatment for
patients with early stage HCC because, not only does the surgery
remove the tumour, but it also removes the organ that harbours
potentially recurrent foci.33 A recent review by Earl and Chapman
concluded that it is vital to consider tumour size, multifocality,
medical comorbidity and geographical factors that affect the
waiting list time and organ availability when considering patients
with early stage HCC for transplant versus a resection.34
The NCDB provides information on a large number of patients
with HCC and outcomes reported from these data are representa-
tive of the combined outcomes of multiple centres across the
United States; however, this data set is not without significant
limitations. For example, while we were able to analyse outcomes in
a subset of patients based on degree of fibrosis based on pathology
reports, we were not able to examine clinically relevant pre-
operative indications of liver dysfunction (ascites and esophageal
varices) or pre-operative laboratory values/composite scores [pro-
thrombin time/international normalized ratio, bilirubin,
creatinine, model for end-stage liver disease (MELD) score and
Child–Turcotte–Pugh score]. This is likely to be of particular sig-
nificance as liver function is a key determinant in the clinical
decision-making process to decide between a liver resection or
transplantation. AJCC pathological staging was not available on all
patients. Hence for patients with stage II disease, given the variabil-
ity in definition and staging system it is possible that there were
patients who were transplanted but who were found to have vas-
cular invasion in the explant post-transplantation. Similarly, other
data was either absent completely (e.g. disease recurrence from
which disease-free survival could be derived), limited in availability
(e.g. chemotherapy data, the use of loco-regional therapy as bridg-
ing therapy toward transplant), or has only recently been included
in the data base (e.g. information from which a MELD score can be
calculated has only been included since 2010).35 Similarly, some
data points were very loosely defined and not amenable to subset
analysis. For example, the ‘chemotherapy’ classification provided
no data regarding timing, route of administration, type of agent
used or number of treatments given. Finally, details on medical
comorbidity were extremely limited and thus could not be
included in our analyses. Certainly, patient comorbidities are also a
key determinant in the clinical decision-making process when
assessing for liver resection and transplantation.
The use of thermal and non-thermal ablation technologies as
both definitive treatment for HCC and as bridging therapy prior
to transplant has been repeatedly demonstrated to improve
survival.37–39 The lack of data related to the use of this therapy is a
limitation of the NCDB, and imposes a possible selection bias as
the distribution of use of ablation between resection and trans-
plant is likely not uniform. Future data collection by the NCDB
would benefit from the addition of this information.
Conclusions
This study represents the largest retrospective analysis of patients
with early stage HCC undergoing either LT or resection LRin the
United States. Based on our analyses, LT is the best surgical treat-
ment for early stage (I/II) HCC in patients with advanced fibrosis
or cirrhosis (Ishak Score 5–6). Conversely LR provides equivalent
outcomes to LT in patients with mild-to-moderate fibrosis (Ishak
Score 0–4) and should be considered as the first surgical option.
However, neither tumor size nor patient AFP level impacted the
overall survival between LT and LR patients. Currently, systems
that incorporate measures of liver function are the preferred
staging system for HCC. Thus, while the NCDB provides a pow-
erful platform for large, multi-centre data set analyses, including
measurements of liver function and outcomes from other treat-
ment approaches would further allow us to define the preferential
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